Achieving Pharmacoequity in the Treatment of Obesity: Strategies for Understanding and Tackling Disparities
Obesity is highly prevalent in the United States (US) and disproportionately impacts historically marginalized populations, including racial and ethnic minorities, sexual and gender minority groups, individuals with disabilities, and people with low socioeconomic status.1 Disparities in obesity prevalence are, in part, manifestations of systemic racism and capitalism. Practices like dependence on the Eurocentric body mass index metric for diagnosis and divestment from low-income neighborhoods and communities of color promote obesogenic environments plagued by predatory advertising, food deserts, sparse green space, stigma, and a perception of hopelessness among individuals with obesity.
